



Press release

Eelco Ockers appointed Executive Vice President Germany at STADA

- As of September 15, 2019, Eelco Ockers will strengthen the worldwide STADA Executive Committee as Executive Vice President Germany.
- Eelco Ockers is a top manager with more than 15 years of experience in large companies such as Reckitt Benckiser, Unilever and Procter & Gamble.
- STADA CEO Peter Goldschmidt: "With Eelco Ockers we have an international brand professional who, together with the Managing Directors of the affiliates, should make our business in Germany even more successful".

Bad Vilbel, June 25, 2019 – As of September 15, Eelco Ockers will strengthen the global STADA Executive Committee as Executive Vice President Germany. The Managing Directors of the German affiliates ALIUD PHARMA GmbH, STADA GmbH and STADAPHARM GmbH will report directly to him in the future. The 43-year-old comes from Reckitt Benckiser, where he most recently served as Regional Director DACH & Nordics, managing the Group's businesses for fast moving consumer goods, hygiene and homecare products in the respective regions. Prior to this, he also worked for Reckitt Benckiser as Managing Director as well as Sales and Marketing Director. In the course of his career, he has also held numerous management positions at Unilever and Procter & Gamble.

Peter Goldschmidt, CEO of STADA: "Germany contributes more than 30 percent to STADA's profits worldwide and is thus the core market of our Group. With Eelco Ockers, we have an international brand professional who, together with the Managing Directors of the German affiliates, should make the generics business and the consumer health business as well as the specialty pharmaceuticals segment even more successful."

"I am very pleased to accompany STADA on its successful growth journey and to support the company together with the team on this path already taken. I am particularly committed to strengthening our brands such as Grippostad and Ladival as well as developing the products and services of our generics affiliate ALIUD PHARMA and specialty pharmaceuticals supplier STADAPHARM," says the experienced top manager Eelco Ockers.

Executive Board: Peter Goldschmidt (CEO) / Mark Keatley / Miguel Pagan Fernandez
Supervisory Board Chairman: Dr. Günter von Au



About STADA Arzneimittel AG

STADA Arzneimittel AG is a publicly-listed company with headquarters in Bad Vilbel, Germany. The company focuses on a two pillar strategy consisting of generics, including specialty pharmaceuticals and non-prescription consumer health products. Worldwide, STADA Arzneimittel AG sells its products in approximately 130 countries. In financial year 2018, STADA achieved adjusted Group sales of EUR 2,330.8 million and adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of EUR 503.5 million. As of December 31, 2018, STADA employed 10,416 people worldwide.

Additional information for journalists:

STADA Arzneimittel AG / Media Relations / Stadastrasse 2–18 / 61118 Bad Vilbel – Germany /

Phone: +49 (0) 6101 603-165 / Fax: +49 (0) 6101 603-215 / E-Mail: press@stada.de

Or visit us on the Internet at www.stada.com/press

Additional information for capital market participants:

STADA Arzneimittel AG / Investor & Creditor Relations / Stadastrasse 2–18 / 61118 Bad Vilbel – Germany /

Phone: +49 (0) 6101 603-4689 / Fax: +49 (0) 6101 603-215 / E-mail: ir@stada.de

Or visit us on the Internet at www.stada.com/investor-relations

Executive Board: Peter Goldschmidt (CEO) / Mark Keatley / Miguel Pagan Fernandez

Supervisory Board Chairman: Dr. Günter von Au